Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Liabilities: 2010-2024

Historic Total Liabilities for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $15.8 million.

  • Altimmune's Total Liabilities rose 126.73% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 126.73%. This contributed to the annual value of $15.8 million for FY2024, which is 4.49% down from last year.
  • Altimmune's Total Liabilities amounted to $15.8 million in FY2024, which was down 4.49% from $16.5 million recorded in FY2023.
  • Altimmune's 5-year Total Liabilities high stood at $21.6 million for FY2022, and its period low was $15.8 million during FY2024.
  • For the 3-year period, Altimmune's Total Liabilities averaged around $18.0 million, with its median value being $16.5 million (2023).
  • In the last 5 years, Altimmune's Total Liabilities surged by 125.34% in 2020 and then fell by 23.55% in 2023.
  • Yearly analysis of 5 years shows Altimmune's Total Liabilities stood at $19.2 million in 2020, then rose by 2.55% to $19.7 million in 2021, then grew by 9.66% to $21.6 million in 2022, then fell by 23.55% to $16.5 million in 2023, then declined by 4.49% to $15.8 million in 2024.